Biotime cordially invites you to join us at the highly anticipated 55th edition of the MEDICA International Hospital and Medical Equipment Exhibition, taking place from November 13th to 16th, 2023, at the renowned Dusseldorf Exhibition Center in Germany. This prestigious event will gather healthcare professionals from across the globe, providing a platform to explore the latest advancements in in-vitro diagnostics, including Biotime's biochemistry luminescence, immunofluorescence, and colloidal gold series. Event Overview:   MEDICA, the International Hospital and Medical Equipment Exhibition in Dusseldorf, Germany, is globally recognized as the largest and most comprehensive medical exhibition of its kind. It showcases a wide range of medical devices, supplies, and equipment, alongside medical communication information technology, medical furniture, medical facility construction technology, and medical equipment management solutions. Throughout the exhibition, there will be numerous seminars, lectures, discussions, and demonstrations, providing attendees with valuable insights into the latest industry trends and technological innovations.   The exhibition serves as a vital platform for industry professionals to connect and exchange knowledge, paving the way for advancements and innovations in the field of medical devices and diagnostic technologies. Visitors will have the opportunity to interact closely with experts from Biotime, specializing in biochemistry luminescence, immunofluorescence, colloidal gold, and other cutting-edge products. Discover their latest offerings and solutions firsthand.   MEDICA 2023 promises to be an exceptional event, fostering collaboration and exploration of the forefront of medical equipment and diagnostic technology. Join us as we collectively strive to advance and innovate in the IVD industry.

Biotime, an innovative healthcare manufacturer, is pleased to announce its remarkable presence and achievements at three prominent international medical exhibitions.   The company showcased its cutting-edge products at the South Africa International Medical Equipment Exhibition - Africa Health (see figure 1.), the Hospital Expo in Indonesia (see figure 2.) and Health Asia in Pakistan (see figure 3.). Through these events, Biotime engaged in fruitful discussions with global customers and partners, exploring new technologies and products in the ever-evolving healthcare industry.   Biotime's immunoassay fluorescence products stole the spotlight at the exhibitions, attracting significant attention from attendees. The products' user-friendly operation and exceptional accuracy in delivering results impressed scholars, experts, and distributors alike. Visitors had the invaluable opportunity to interact with Biotime's technical team, gaining profound insights into the technological features and application advantages of the company's immunoassay fluorescence platform. (figure1. Africa Health 2023) (figure 2.Hospital Expo 2023) (figure 3.Health Asia 2023) At present, Biotime's immunoassay fluorescence testing platform covers a wide range of series, including cardiovascular, inflammation, hormones, thyroid function, diabetes, and renal injury. The platform boasts an impressive turnaround time, with results available in as fast as 3 minutes. Additionally, it seamlessly integrates with various instruments, such as the single-channel BIOT-YG-I Immunoassay Fluorescence Analyzer, the six-channel FLI-600 Dry Fluorescence Immunoassay Analyzer, and the FLI-4000 Fully Automated Dry Fluorescence Immunoassay Analyzer. This versatility effectively caters to the diverse testing needs of different medical institutions.   We are elated with with the success and acclaim garnered at these international medical exhibitions. Our groundbreaking immunoassay fluorescence products have captured the industry's interest, and we take immense pride in our contribution to advancing healthcare technologies on a global scale. Our dedication to driving progress in the medical industry remains steadfast, as we continue to develop solutions that enhance patient care.

This October, Biotime is excited to present its diverse range of POCT (Point-of-Care Testing) solutions at international exhibitions in South Africa, Indonesia, and Pakistan. We extend a warm welcome to both new and existing friends to visit us and participate in meaningful discussions.   Africa Health 2023 Date: October 17th-19th, 2023 Address: Gallagher Convention Centre, Johannesburg Booth: 2.B20 Event Overview: Africa Health has been the leading healthcare event in Africa, showcasing advanced medical technologies, expert conferences, and fostering important professional networks. It serves as a crucial gathering place for professionals in hospitals, pharmaceuticals, medical research, and retail industries from Africa and around the world. In 2022, the event attracted over 300 exhibitors from 33 countries and nearly ten thousand visitors.   Hospital Expo 2023 Date: October 18th-21st, 2023 Address: Jakarta Convention Center, Indonesia Booth: M47 Event Overview: Hospital Expo is Indonesia's most professional and influential medical industry exhibition, with a 30-year history. It has received strong support from the Ministry of Health and the Indonesian Hospital Association, becoming a dedicated platform for collaboration between industry suppliers, purchasers, and international medical manufacturers.   Health Asia 2023 Date: October 19th-21st, 2023 Venue: Karachi Expo Centre, Pakistan Booth: B69-B70 Event Overview: Asia Health International Exhibition and Conference is Pakistan's largest annual healthcare and medical industry event. It is the only UFI-certified professional medical exhibition in Pakistan and enjoys extensive support from the Ministry of Health, relevant government departments and officials, the Pakistan Medical Association, and government/private healthcare institutions. The exhibition is highly specialized and exclusively open to all doctors, professional buyers, healthcare professionals, medical companies, and medical students.   During these exhibitions, Biotime will showcase a comprehensive range of in vitro diagnostic testing solutions, including chemiluminescence, immunofluorescence, and colloidal gold platforms. We invite all our valued customers, both new and old, to visit our booth and engage in discussions about industry advancements and opportunities.

On September 28th, the three-day Medic West Africa, the International Medical Equipment Exhibition, came to a successful end at the Expo Center in Lagos, Nigeria. Over 150 companies from more than 30 countries and regions participated in this grand event. Biotime showcased its diverse platform of Point-of-Care Testing (POCT) solutions at the exhibition, engaging in in-depth discussions and cooperation with global customers and partners. The immunofluorescence series BIOT-YG-I and FLI-100 from Biotime Biotechnology caught the attention of many international customers with their simplicity of operation and accurate results. These solutions not only provide a range of POCT testing options for cardiac markers, inflammation, hormones, and thyroid, but also deliver results in as fast as 3 minutes, efficiently supporting medical institutions in conducting relevant testing projects. As a national high-tech enterprise specializing in the research, development, production, and sales of in-vitro diagnostic reagents and instruments, Biotime Biotechnology has always adhered to its mission of practical innovation and technological service for health. With excellent products and services, Biotime has gained wide recognition from customers. In the future, Biotime will continue to stay true to its mission and forge ahead, contributing the "Biotime Power" to the development of the medical and health industry. Meanwhile, Biotime shows no signs of slowing down in October. We are about to participate in three medical exhibitions: the Africa Health in South Africa, the Indonesian Hospital Expo and Health Asia in Pakistan. We hope that you and your company representatives can join us, progress together, and achieve win-win cooperation. We firmly believe that these events will provide Biotime with a better platform for promotion, exchange insights with international peers on new products, technologies, and solutions, facilitate collaborative discussions, and jointly plan the path for further development in the healthcare industry.

From Sep. 13th-5th, 2023, the Medical Fair Thailand 2023 was successfully held at the Bangkok International Trade and Exhibition Centre in Thailand. Over 12,000 medical professionals from more than 80 countries and regions gathered to discuss the latest developments in the healthcare industry. Biotime's multi-platform POCT solutions, including chemiluminescence, immunofluorescence, and colloidal gold, made a remarkable appearance at this grand event. Among Biotime's star products, BIOT-YG-I, FLI-100, FLI-600, and FLI-4000 were prominently featured at the international exhibition. These products were highly praised for their flexible and rapid testing methods, offering a wide range of POCT testing solutions for conditions such as cardiac markers, inflammation, hormones, and thyroid function. Results can be obtained in as little as 3 minutes, effectively meeting the testing needs of various medical institutions. In addition to these products, Biotime's POCT solutions for COVID-19, monkeypox, diabetes, and more garnered significant attention at the exhibition. Many clients visited the booth to explore these solutions, engage in discussions, and explore potential business collaborations. In addition to the Medical Fair in Thailand, during nearly the same period, Biotime also made appearances at several other significant healthcare industry exhibitions. These included the 18th Vietnam International Medical Exhibition (PHARMEDI VIETNAM) and the 8th East Africa Kenya International Medical Equipment Exhibition (Medic East Africa). These events provided valuable platforms for Biotime to engage with international colleagues, exchange insights on new products, technologies, and solutions, foster discussions on collaboration, and collectively chart a path for further development in the healthcare sector. With over a decade of dedicated experience in the IVD field, Biotime Biotechnology has established a strong foothold. We have expertise spanning multiple technological platforms, including chemiluminescence, molecular diagnostics, chromatography, mass spectrometry, dry chemistry, electrochemistry, fluorescence immunoassay, and colloidal gold. Our extensive portfolio comprises more than 50 testing items, catering to diverse usage scenarios. Looking ahead, while maintaining a strong presence in the domestic market, Biotime is committed to expanding its footprint in international markets. We are poised to contribute our expertise to the global biopharmaceutical industry's advancement and growth

In the afternoon of June 30, the inauguration ceremony of Biotime Biotechnology (Xiamen Biotime Biotechnology co., LTD.) Instrument R&D and Production Center was successfully held. The inauguration ceremony was attended by corporate leaders and R&D team, including Biotime Biotechnology Chairman Zhang Guofeng, Deputy General Manager Huang Jianguo, Deputy General Manager Zhuang Yanghuang and Instrument R&D Director Yin Yandong. At the inauguration ceremony, Zhang Guofeng, Chairman of Biotime Biotechnology, delivered a speech. Mr. Zhang said that the establishment of Instrument R&D and Production Center is another important initiative on the way of Biotime's development, and he hoped that the instrument R&D team would contribute to the high-quality development of biomedical business with the creativity and super execution of keeping up with the times under the new starting point. After that, Yin Yandong, the director of instrument R&D, delivered a speech. Mr. Yin said that in the future, the instrument R&D and production center will continue to be customer-oriented, market demand-oriented, pioneering and enterprising, and do what little one can to help of Biotime. Innovation is the driving force of enterprise development. The establishment of Biotime Biotechnology Instrument R&D and Production Center is not only an important step for the enterprise to adhere to the product as the purpose and innovation as the priority, but also will further promote the progress of enterprise R&D technology, enhance the market competitiveness and business coverage of the enterprise, and contribute to the high-quality development of biomedical business.

6-9 Feb., 2023，Medlab Middle East is scheduled to take place in Dubai World Trade Center, Dubai. We are waiting for you at booth #Z2.A30 with our new products and solutions, including but not limited to: rapid test, FIA analyzer, CLIA analyzer. FIA Analyzer Biotime team will show 3 star products, BIOT-YG-I, FLI-100 and FLI-600 FIA analyzers. CLIA Analyzer Biotime will show CLi-1600, which is a star product of CLIA analyzer. Diabetes Solution Diabetes is a disease of widespread concern in the world. At the fair, HLC-100 will be showcased, which is the GOLD STANDARD for the detection of HbA1c. The product has 12 detection channels and can get results within 2 minutes. In addition, there are also blood glucose, blood ketone, uric acid test instruments on display.  The test results are quick and accurate, economical and practical, and can effectively meet the needs of families. Rapid Test Besides, rapid test products will also be displayed, which can be used effectively in the diagnosis of respiratory infections,  mosquito-borne diseases and sexually transmitted diseases. 6-9 Feb., 2023，see you in Medlab Middle East, Dubai World Trade Center.

Every fall and winter, viral respiratory illnesses like the common cold and seasonal flu keep kids out of school and social activities. But this year, more children than usual are ending up at emergency departments and hospitals. Resepiratory Viral Infections like Human Adenovirus (HADV), Respiratory  Syncytial Virus (RSV) and Influenza (Flu) can be dangerous for some infants and young children. Country estimates of the number of clinical pneumonia cases among children aged less than 5 years were assembled into six WHO regions (African Region, Region of the Americas, SouthEast Asia Region, European Region, Eastern Mediterranean Region and Western Pacific Region) as well as into developing and developed regions. These aggregated results together with estimates of new episodes per child-year and the number of severe episodes are shown in the table. It is one of major public health interest to assess the distribution of these estimated 156 million episodes by regions and countries to assist planning for preventive interventions and case management at community and facility levels. Identifying respiratory viral infections can be hard since seasonal ADV, RSV and Flu viruses are characterized by a sudden onset of fever, cough, headache, muscle and joint pain, severe malaise (feeling unwell), sore throat and a runny nose. Doctors may suspect respiratory infections based on the findings of a physical exam and the time of year the symptoms occur. During the exam, the doctor will listen to the lungs with a stethoscope to check for wheezing or other abnormal sounds. With similar symptoms for ADV, RSV and Flu A/B, healthcare professionals need to quickly determine which infection is potentially present. Characteristic testing helps healthcare professionals at the point of care to quickly diagnose and differentiate infections with any of the three respiratory viruses and aid in pursuing appropriate courses of action, including patient and pandemic management decisions. Also, it enables scaling up test capacities during flu season to meet the need for extensive testing during peak periods. Xiamen Biotime offers convenient, affordable and rapid diagnostic Point-of-Care-Testing for respiratory infections such as ADV, RSV and Flu A/B. The four main uses and purposes Protect others: virus-infected individual can be isolated to prevent the spread of the virus. Differentiation between ADV, RSV and Flu A/B: A single sample can be used to distinguish between ADV, RSV and Flu A/B for fast testing of symptomatic patients. Optimize patient care: The earliest starting treatment is when the medication is most effective. Rapid testing where it is needed most: The ability to conduct testing outside the lab at any time and anywhere to support testing strategies and increase capacity. Conclusion About 156 million new episodes of childhood clinical pneumonia occurred globally in 2000, more than 95% of them in developing countries. Of all the pneumonia cases occurring in th...